131 related articles for article (PubMed ID: 33180662)
1. Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression.
Lei R; Miao L
Cancer Biol Ther; 2020 Dec; 21(12):1081-1086. PubMed ID: 33180662
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast.
Wang J; Zhang X; He J; Yang M; Tang J; Li X; Tang H; Xie X
Med Oncol; 2014 Sep; 31(9):172. PubMed ID: 25119504
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast.
Lei T; Pu T; Wei B; Fan Y; Yang L; Shen M; Chen M; Yang J; Zhang Y; Zhang Z; Bu H
J Clin Pathol; 2022 Jan; 75(1):18-23. PubMed ID: 33214199
[TBL] [Abstract][Full Text] [Related]
4. Breast Metaplastic Squamous Cell Carcinoma Diagnosed with Fine Needle and Core Biopsy: A Case Study.
Cha N; Wang S; Lv M; Wang DW; Zhang XJ; Zheng M; Tian LX
Am J Case Rep; 2018 Feb; 19():203-206. PubMed ID: 29472521
[TBL] [Abstract][Full Text] [Related]
5. Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype.
Shui R; Li A; Yang F; Zhou X; Yu B; Xu X; Yang W
Int J Clin Exp Pathol; 2014; 7(8):5203-9. PubMed ID: 25197398
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
9. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
10. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
[TBL] [Abstract][Full Text] [Related]
11. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
12. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
16. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
18. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
19. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Giuliani S; Ciniselli CM; Leonardi E; Polla E; Decarli N; Luchini C; Cantaloni C; Gasperetti F; Cazzolli D; Berlanda G; Bernardi D; Pellegrini M; Triolo R; Ferro A; Verderio P; Barbareschi M
Virchows Arch; 2016 Jul; 469(1):45-50. PubMed ID: 27097809
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast].
Gao BB; Zheng Q; Yu L; Luo DJ; Nie X; Xu X
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):843-849. PubMed ID: 36097900
[No Abstract] [Full Text] [Related]
[Next] [New Search]
